• MARCH 1, 2018
    • 0
    Solco Healthcare US receives FDA approval for its generic to Abilify® tablets

    Solco Healthcare US receives FDA approval for its generic to Abilify® tablets

    CRANBURY, NJ – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Abilify® Tablets (Aripiprazole tablets), 2, 5, 10, 15, 20 and 30mg.  The product is available for shipment now. Aripiprazole tablets are are indicated for the following: (A) Bipolar I disorder, (B) Irritability, associated

    Read more
    • APRIL 25, 2018
    • 0
    SOLCO HEALTHCARE US ANNOUNCES THE LAUNCH OF ENTECAVIR TABLETS

    SOLCO HEALTHCARE US ANNOUNCES THE LAUNCH OF ENTECAVIR TABLETS

    CRANBURY, NJ., April 25, 2018 – Solco Healthcare is proud to announce the launch of Entecavir Tablets, 0.5mg and 1mg, a generic equivalent of Baraclude® Tablets by Bristol-Myers Squibb Company.  Solco is offering Entecavir Tablets, 0.5mg and 1mg, in 30-count bottles to its customers. The product is available for shipment immediately.  Entecavir tablets are used to treat chronic

    Read more
    • APRIL 3, 2018
    • 0
    SOLCO HEALTHCARE US ANNOUNCES THE LAUNCH OF CLONIDINE HCL ER TABLETS

    SOLCO HEALTHCARE US ANNOUNCES THE LAUNCH OF CLONIDINE HCL ER TABLETS

    Cranbury, NJ., April 3, 2018.  Solco Healthcare announced today the launch of Clonidine Hydrochloride Extended-Release Tablets, 01.mg, a generic version of Kapvay® Tablets by Concordia Pharmaceuticals Inc.  The product is used for the treatment of attention-deficit/hyperactivity disorder (ADHD). The U.S. Food and Drug Administration (FDA) has granted final approval of its Abbreviated New Drug Application for Clonidine

    Read more
    • JUNE 18, 2018
    • 0
    SOLCO HEALTHCARE US ANNOUNCES THE FDA APPROVAL OF FENOFIBRATE TABLETS, 48mg and 145mg

    SOLCO HEALTHCARE US ANNOUNCES THE FDA APPROVAL OF FENOFIBRATE TABLETS, 48mg and 145mg

    CRANBURY, NJ — Solco Healthcare is proud to announce its FDA approval for Fenofibrate tablets, 48 mg and 145 mg, which is an AB-rated equivalent to Tricor® by Abbvie. Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to

    Read more

Photostream